Chemomab Therapeutics announces positive FDA feedback, advancing Nebokitug Phase 3 design.

Chemomab Therapeutics has completed the phase 3 design of Nebokitug, a drug for primary sclerosing cholangitis (PSC), following positive feedback from the FDA. The company has also received guidance from the EMA supporting a single phase 3 registration trial using a clinical event composite endpoint. New data from the phase 2 SPRING trial shows favorable safety and consistent improvements in key biomarkers in PSC patients treated with Nebokitug for up to 48 weeks. The company expects a cash runway through the end of Q4 2026.